Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease

Blood

Volumn 113, Issue 10, 2009, Pages 2352-2362

  Das, Rupali ^a   Chen, Xiao ^a   Komorowski, Richard ^a   Hessner, Martin J ^a   Drobyski, William R ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Bone Marrow Transplant Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 23; LIPOPOLYSACCHARIDE;

ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW TRANSPLANTATION; COLON; COLON INJURY; CONDITIONING; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DONOR; DOWNSTREAM PROCESSING; GENE TRANSLOCATION; GRAFT VERSUS HOST REACTION; INFLAMMATION; MICROENVIRONMENT; MOUSE; NONHUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TISSUE SPECIFICITY;

EID: 63849105635     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-175448     Document Type: Article

References (51)

1. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inacti-vation of host antigen-presenting cells. Science.1999;285: 412-415.
2. + T cells to elicit hepatic graft-versus-host disease. J Immunol. 2002;169:7111-7118.
3. Schmaltz C, Alpdogan O, Muriglan SJ, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood.2002;97:2886-2895.
4. Van den Brink MR, Burakoff SJ. Cytolytic pathways in hematopoietic stem-cell transplantation.Nature Rev Immunol. 2002;2:273-281.
5. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996;183: 2645-2656.
6. Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172: 7393-7398.
7. Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood. 2002;99:1442-1448.
8. Clark FJ, Freeman L, Dzionek A, et al. Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease. Transplantation. 2003;75:221-225.
9. Benichou G, Takizawa AP, Olson CA, McMillan M,Sercarz EE. Donor major histocompatibility complex class I peptides are presented by recipient MHC molecules during graft rejection. J Exp Med.1992;175:305-308.
10. Liu Z, Braunstein NS, Suciu-Foca N. T cell recognition of allopeptides in context of syngeneic MHC. J Immunol. 1992;148:35-40.
11. Matte CC, Liu J, Anderson BE, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987-992.
12. Tivol EA, Komorowski R, Drobyski WR. Emergent autoimmunity in graft versus host disease. Blood. 2005;105:4887-4893.
13. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
14. Koch F, Stanzl U, Jennewen P, et al. High level IL-12 production by murine dendritic cells: up-regulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med. 1996;184:741-746.
15. Reis e Sousa C, Hieny S, Scharton-Kersten T, et al. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleu-kin 12 by dendritic cells and their redistribution to Tcell areas. J Exp Med. 1997;186:1819-1829.
16. Cella M, Scheidegger D, Palmer-Lehmann K,Lane P, LanzavecchiaA, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-Thelp viaAPC activation.J Exp Med. 1996;184:747-752.
17. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-725.
18. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev. 2004;202:96-105.
19. Belladonna ML, Renauld J-C, Bianchi R, et al. IL-23 and IL-12 have overlapping, but distinct,effects on murine dendritic cells. J Immunol. 2002;168:5448-5454.
20. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate pathology. Immunity. 2006;25:309-318.
21. Hue S, Ahern P, Buonocore S, et al. Interleukin 23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006;203:2473-2483.
22. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for Tcell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest.2006;116:1310-1316.
23. Hoeve MA, Savage NDL, de Boer T, et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol. 2006; 36:661-670.
24. Parham C, Chirica M, Timans J, et al. Areceptor for the heterodimeric cytokine IL-23 is composed of IL-12R(31 and a novel cytokine receptor sub-unit, IL-23R. J Immunol. 2002;168:5699-5708.
25. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17 deficient mice. J Immunol. 2003;171:6173-6177.
26. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:566-573.
27. h17 cells is responsible for the autoimmune-mediated pathology in chronic graft versus host disease.Blood. 2007;110:3804-3813.
28. Chen Y, Langrish CL, McKenzie B, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encepha-lomyelitis. J Clin Invest. 2006;116:1317-1326.
29. Cua DJ, Sherlock J, Chen Y, et al. Interleukin 23 rather than interleukin 12 is the critical cytokine for autoimmune inflammation of the brain. Nature.2003;421:744-748.
30. Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney AL, de Sauvage FJ. Compromised humoral and delayed-type hypersensitivity responses in IL-23 deficient mice. J Immunol. 2004;172:2827-2833.
31. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor α production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft versus host disease. J Clin Invest. 1998;102:1882-1891.
32. Iwami K, Matsuguchi T, MasudaA, Kikuchi T,Musikacharoen T, Yoshikai Y. Cutting edge: naturally occurring soluble forms of mouse toll-like receptor 4 inhibits lipopolysaccharide signaling.J Immunol. 2001;165:6682-6686.
33. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:2001-2007.
34. Williamson E, Garside P, Bradley JA, Mowat AM. IL-12 is a central mediator of acute graft versus host disease in mice. J Immunol. 1996;157:689-699.
35. Hill GR, Crawford JM, Cooke KR, Brinson YS,Pan L, Ferrara JL. Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204-3213.
36. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft versus host disease and preserves graft versus leukemia activityafter experimental bone marrowtransplantation. J Clin Invest.2001;107:1581-1589.
37. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science. 1998;282: 2085-2088.
38. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431-1433.
39. Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999; 189:1777-1782.
40. Elmaagacli AH, Koldenhoff M, Landt O, Beelen DW. Relation of an interleukin-23 receptor gene polymorphism to graft versus host disease after hematopoietic cell transplantation. Bone Marrow Transplant. 2008;41:821-826.
41. h17 and regulatoryTcells. Nature. 2006;441:235-238.
42. h-17 cell mediated pathology. Nat Immunol. 2007;8:1390-1397.
43. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. IL-17 produced by lymphocytes and neutrophils is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol. 2003;170:2106-2112.
44. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor a during graft versus host disease. J Exp Med. 1992;175:405-413.
45. Mowat AC. Antibodies to IFN-γ prevent immuno-logically mediated intestinal damage in murine graft versus host disease. Immunology. 1989;68: 18-23.
46. Burman AC, Banovic T, Kuns RD, et al. IFN7 differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood. 2007;110:1064-1072.
47. h17- independent manner.Int Immunol. 2007;19:1431-1440.
48. Izcue A, Hue S, Buonocore S, et al. Interleukin 23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity. 2008;28:559-570.
49. Teshima T, Ordemann R, Reddy P, et al. Acute graft versus host disease does not require alloan-tigen expression on host epithelium. Nat Med. 2002;8:575-581.
50. h17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967-974.
51. Chakraverty R, Sykes M. The role of antigen presenting cells in triggering graft versus host and graft versus leukemia. Blood. 2007;110:9-17.